Table 2.

Summary of the sensitivity analysis

Parameter		Baseline hydrocele average estimate (range)	Baseline lymphedema average estimate (range)	Sources
Pre-control burden
Percentage of the at-risk population that develop clinical disease		2.08% (1.04%)	1.25% (0.63%)	[16]
Disability weights
Disability weights related to chronic disease		0.128 (0.086–0.180)	0.109 (0.073–0.154)	[17]
Disability weight for ADL episodes		0.051 (0.032–0.074)	0.051 (0.032–0.074)	[17]
Disease progression & incidence rates
Percentage of clinical patients who experience ADL episodes per year		70% (45–90%)	95% (90–95%)	[26–34]
Frequency of ADL episodes for clinical patients (in absence of MDA)		2 (0–7) per year	4 (0–7) per year	[26–34]
Average duration of an ADL episode		4 (1–9) days	4 (1–9) days	[26–34]
Mean age of the benefit cohorts (years)		Cohort 1: 20 (30) Cohort 2: 20 (30) Cohort 3: 30 (40)	Cohort 1: 20 (30) Cohort 2: 20 (30) Cohort 3: 30 (40)
Impact of treatment
The reduction in transmission experienced by the treated population (Benefit cohort 1)		Year 1: 50% (35%) Year 2: 75% (53%) Year 3: 88% (62%) Year 4: 94% (66%) Year 5 95% (67%)	Year 1: 50% (35%) Year 2: 75% (53%) Year 3: 88% (62%) Year 4: 94% (66%) Year 5 95% (67%)	[12]
Reduction in the frequency of ADL episodes by MDA (Benefit cohort 3)		50% (15–88%)	50% (15–88%)	[35–37]
Percentage of chronic disease alleviated by MDA (Benefit cohort 3)		10% (0–20%)	15% (0–30%)	[35, 38–43]

Based on Chu et al. [10], though updated where appropriate

ADL acute adenolymphangitis, DALY disability-adjusted life year, MDA mass drug administration